The value of radiosynoviorthesis for treatment of chronic synovitis in hemophilic joint disease

Q J Nucl Med Mol Imaging. 2022 Dec;66(4):334-344. doi: 10.23736/S1824-4785.22.03474-4. Epub 2022 Sep 15.

Abstract

Chronic synovitis is contributing to the development of arthropathy in hemophilia A and B. In most patients with severe and moderate hemophilia, during lifetime, joint damage progresses despite early prophylaxis and intense treatment with coagulation factor concentrates. Recurrent hemorrhages into the joints and subclinical bleeding lead to chronic inflammation of the synovium, neoangiogenesis and remodeling, sustaining a vicious circle of bleeding-remodeling-bleeding and progression of osteochondral damage. Imaging techniques including ultrasound and MRI are able to early visualize synovitis and osteochondral changes. Early detection and sustained therapy of synovitis are important preconditions to prevent further deterioration of joint status. Chronic synovitis requires intensified substitution of coagulation factors and concomitant analgetic, antiphlogistic and physical therapy. The value of early radiosynoviorthesis (RSO) as effective method to control ongoing synovitis is discussed here. RSO is recommended as first choice therapy in case of persistant chronic synovitis, recorded in both national and international guidelines.

MeSH terms

  • Chronic Disease
  • Hemarthrosis / complications
  • Hemarthrosis / diagnostic imaging
  • Hemarthrosis / radiotherapy
  • Hemophilia A* / complications
  • Hemophilia A* / radiotherapy
  • Humans
  • Inflammation / complications
  • Synovitis* / complications
  • Synovitis* / diagnostic imaging
  • Synovitis* / radiotherapy